The translation of in-house imaging AI research into a medical device ensuring ethical and regulatory integrity.

Journal: European journal of radiology
PMID:

Abstract

This manuscript delineates the pathway from in-house research on Artificial Intelligence (AI) to the development of a medical device, addressing critical phases including conceptualization, development, validation, and regulatory compliance. Key stages in the transformation process involve identifying clinical needs, data management, model training, and rigorous validation to ensure AI models are both robust and clinically relevant. Continuous post-deployment surveillance is essential to maintain performance and adapt to changes in clinical practice. The regulatory landscape is complex, encompassing stringent certification processes under the EU Medical Device Regulation (MDR) and the upcoming EU AI Act, which imposes additional compliance requirements aimed at mitigating AI-specific risks. Ethical considerations such as, emphasizing transparency, patient privacy, and equitable access to AI technologies, are paramount. The manuscript underscores the importance of interdisciplinary collaboration, between healthcare institutions and industry partners, and navigation of commercialization and market entry of AI devices. This overview provides a strategic framework for radiologists and healthcare leaders to effectively integrate AI into clinical practice, while adhering to regulatory and ethical standards, ultimately enhancing patient care and operational efficiency.

Authors

  • Filippo Pesapane
    Postgraduation School in Radiodiagnostics, Università Degli Studi di Milano, Via Festa del Perdono 7, 20122, Milan, Italy. filippo.pesapane@unimi.it.
  • Mathias K Hauglid
    Faculty of Law, University of Tromsø-The Arctic University of Norway.
  • Marzia Fumagalli
    Technology Transfer Office, IEO European Institute of Oncology IRCCS, Milan, Italy. Electronic address: marzia.fumagalli@ieo.it.
  • Lena Petersson
    School of Health and Welfare, Halmstad University, Box 823, 301 18, Halmstad, Sweden. lena.petersson@hh.se.
  • Anagha P Parkar
    Department of Radiology, Haraldsplass Deaconess Hospital, Bergen, Norway. apparkar@gmail.com.
  • Enrico Cassano
    Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Denis Horgan
    European Alliance for Personalised Medicine, Brussels, Belgium, denishorgan@euapm.eu.